Epidemiological Study to Describe Non-small-cell Lung Carcinoma (NSCLC) Clinical Management Patterns in MENA. Lung-EPICLIN/ KSA
This study is ongoing, but not recruiting participants.
Sponsor:
AstraZeneca
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01330862
First received: March 30, 2011
Last updated: December 11, 2012
Last verified: December 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The study is to provide accurate, reliable information on NSCLC clinical management across MENA (Middle East North Africa) countries in order to detect unmet medical needs of this disease, it is a purely observational study; therefore patients are not assigned to a particular therapeutic strategy beforehand by a protocol. Treatment will be according to current clinical practice.
| Condition |
|---|
|
NSCLC Patient Characteristics |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Epidemiological Study to Describe NSCLC Clinical Management Patterns in MENA. Lung-EPICLIN/ KSA |
Resource links provided by NLM:
Further study details as provided by AstraZeneca:
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
All NSCLC patients attending the responsible department of treating this type of patients (e.g. Oncology Department) for the first time (regardless of whether the patient is diagnosed with locally, advanced or metastatic disease) at the participating sites from the first of April 2011 to the end of September 2011
Criteria
Inclusion Criteria:
- Confirmed NSCLC diagnosis (e.g. bronchoscope or FNAB), all stages, men and women, attending the responsible department of treating this type of patients for the first time between April 1st 2011 and March 31 2012, for PRO sub-sample: ability to read and write since they will be asked to participate in the PRO part of the study. Selection will not be based on the disease stage of each patient, in order to avoid a selection bias
Exclusion Criteria:
- According to the study design there will not be any exclusion criteria in order to provide a high validity and to obtain the most accurate real daily practice information.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01330862
Locations
| Saudi Arabia | |
| Research Site | |
| Qassim, Central, Saudi Arabia | |
| Research Site | |
| Riyadh, Central, Saudi Arabia | |
| Research Site | |
| Dammam, Eastern, Saudi Arabia | |
| Research Site | |
| Jeddah, Western, Saudi Arabia | |
Sponsors and Collaborators
AstraZeneca
Investigators
| Study Chair: | Dr. Abdul Rahman Jazieh | King Fahad National Guard Hospital |
| Principal Investigator: | Dr. Ahmed Abdulwarith | King Fahad Specialist Hospital |
| Principal Investigator: | Dr. Rasha Moastafa | King Fahad Medical City |
| Principal Investigator: | Dr. Sherif Wafa | Prince Faisal Bin Bander oncology centre |
| Principal Investigator: | Dr. Maged Mansour | Dr. Erfan & Bagedo Hospital |
| Principal Investigator: | Dr. Mohamed Rahhal | King Fahad Specialist Hospital |
More Information
No publications provided
| Responsible Party: | AstraZeneca |
| ClinicalTrials.gov Identifier: | NCT01330862 History of Changes |
| Other Study ID Numbers: | NIS-MENA-SA-IRS-2010/01 |
| Study First Received: | March 30, 2011 |
| Last Updated: | December 11, 2012 |
| Health Authority: | Saudi Arabia: Ethics Committee |
Keywords provided by AstraZeneca:
|
patient outcomes |
Additional relevant MeSH terms:
|
Carcinoma, Non-Small-Cell Lung Carcinoma, Bronchogenic Bronchial Neoplasms Lung Neoplasms Respiratory Tract Neoplasms |
Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases |
ClinicalTrials.gov processed this record on May 19, 2013